These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29643987)

  • 41. Comparison of breast cancer risk factors among molecular subtypes: A case-only study.
    Zhang L; Huang Y; Feng Z; Wang X; Li H; Song F; Liu L; Li J; Zheng H; Wang P; Song F; Chen K
    Cancer Med; 2019 Apr; 8(4):1882-1892. PubMed ID: 30761775
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A network pharmacology-based investigation of brugine reveals its multi-target molecular mechanism against Breast Cancer.
    Qayoom H; Alkhanani M; Almilaibary A; Alsagaby SA; Mir MA
    Med Oncol; 2023 Jun; 40(7):202. PubMed ID: 37308611
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of Clinical Subtypes of Breast Cancer within the Claudin-Low Molecular Cluster Reveals Distinct Phenotypes.
    Voutsadakis IA
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345027
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adaptive reprogramming of the breast cancer kinome.
    Stuhlmiller TJ; Earp HS; Johnson GL
    Clin Pharmacol Ther; 2014 Apr; 95(4):413-5. PubMed ID: 24413269
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association between mammographic density and basal-like and luminal A breast cancer subtypes.
    Razzaghi H; Troester MA; Gierach GL; Olshan AF; Yankaskas BC; Millikan RC
    Breast Cancer Res; 2013; 15(5):R76. PubMed ID: 24008056
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.
    Ihemelandu CU; Leffall LD; Dewitty RL; Naab TJ; Mezghebe HM; Makambi KH; Adams-Campbell L; Frederick WA
    J Surg Res; 2007 Nov; 143(1):109-18. PubMed ID: 17950079
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.
    Hennessy BT; Gonzalez-Angulo AM; Stemke-Hale K; Gilcrease MZ; Krishnamurthy S; Lee JS; Fridlyand J; Sahin A; Agarwal R; Joy C; Liu W; Stivers D; Baggerly K; Carey M; Lluch A; Monteagudo C; He X; Weigman V; Fan C; Palazzo J; Hortobagyi GN; Nolden LK; Wang NJ; Valero V; Gray JW; Perou CM; Mills GB
    Cancer Res; 2009 May; 69(10):4116-24. PubMed ID: 19435916
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Profiling global kinome signatures of the radioresistant MCF-7/C6 breast cancer cells using MRM-based targeted proteomics.
    Guo L; Xiao Y; Fan M; Li JJ; Wang Y
    J Proteome Res; 2015 Jan; 14(1):193-201. PubMed ID: 25341124
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Distinct patterns of promoter CpG island methylation of breast cancer subtypes are associated with stem cell phenotypes.
    Park SY; Kwon HJ; Choi Y; Lee HE; Kim SW; Kim JH; Kim IA; Jung N; Cho NY; Kang GH
    Mod Pathol; 2012 Feb; 25(2):185-96. PubMed ID: 22037257
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.
    Jézéquel P; Loussouarn D; Guérin-Charbonnel C; Campion L; Vanier A; Gouraud W; Lasla H; Guette C; Valo I; Verrièle V; Campone M
    Breast Cancer Res; 2015 Mar; 17():43. PubMed ID: 25887482
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A novel approach to triple-negative breast cancer molecular classification reveals a luminal immune-positive subgroup with good prognoses.
    Prado-Vázquez G; Gámez-Pozo A; Trilla-Fuertes L; Arevalillo JM; Zapater-Moros A; Ferrer-Gómez M; Díaz-Almirón M; López-Vacas R; Navarro H; Maín P; Feliú J; Zamora P; Espinosa E; Fresno Vara JÁ
    Sci Rep; 2019 Feb; 9(1):1538. PubMed ID: 30733547
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
    Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
    Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy.
    Prat A; Fan C; Fernández A; Hoadley KA; Martinello R; Vidal M; Viladot M; Pineda E; Arance A; Muñoz M; Paré L; Cheang MC; Adamo B; Perou CM
    BMC Med; 2015 Dec; 13():303. PubMed ID: 26684470
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting a cell state common to triple-negative breast cancers.
    Muellner MK; Mair B; Ibrahim Y; Kerzendorfer C; Lechtermann H; Trefzer C; Klepsch F; Müller AC; Leitner E; Macho-Maschler S; Superti-Furga G; Bennett KL; Baselga J; Rix U; Kubicek S; Colinge J; Serra V; Nijman SM
    Mol Syst Biol; 2015 Feb; 11(1):789. PubMed ID: 25699542
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
    Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
    Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays.
    Boyd ZS; Wu QJ; O'Brien C; Spoerke J; Savage H; Fielder PJ; Amler L; Yan Y; Lackner MR
    Mol Cancer Ther; 2008 Dec; 7(12):3695-706. PubMed ID: 19056674
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Systematic analysis of in vitro chemosensitivity and mib-1 expression in molecular breast cancer subtypes.
    Liedtke C; Packeisen J; Hess KR; Vogt U; Kiesel L; Kersting C; Korsching E; Brandt B; Buerger H
    Eur J Cancer; 2012 Sep; 48(13):2066-74. PubMed ID: 21920731
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Proteogenomics connects somatic mutations to signalling in breast cancer.
    Mertins P; Mani DR; Ruggles KV; Gillette MA; Clauser KR; Wang P; Wang X; Qiao JW; Cao S; Petralia F; Kawaler E; Mundt F; Krug K; Tu Z; Lei JT; Gatza ML; Wilkerson M; Perou CM; Yellapantula V; Huang KL; Lin C; McLellan MD; Yan P; Davies SR; Townsend RR; Skates SJ; Wang J; Zhang B; Kinsinger CR; Mesri M; Rodriguez H; Ding L; Paulovich AG; Fenyö D; Ellis MJ; Carr SA;
    Nature; 2016 Jun; 534(7605):55-62. PubMed ID: 27251275
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differential expression of epithelial–mesenchymal transition and stem cell markers in intrinsic subtypes of breast cancer.
    Pomp V; Leo C; Mauracher A; Korol D; Guo W; Varga Z
    Breast Cancer Res Treat; 2015 Nov; 154(1):45-55. PubMed ID: 26467042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.